COMP <GO>
EBS vs JNJ // GROSS PROFIT MARGIN
Emergent BioSolutions Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EBS 2
— JNJ 8
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
gross-margins
56.10%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 56.10% | 67.90% | -11.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 25.50% | -16.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 18.5x | -11.90 | EBS | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 13.50% | 34.70% | -21.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 28.50% | -21.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -28.80% | 6.00% | -34.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 5.59 | -4.18 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 62.1 | -9.12 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 23.0x | -16.50 | EBS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $370.2M | $662.49B | -$662.12B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | JNJ REV | EBS GROSS % | JNJ GROSS % | EBS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $94.19B | 56.1% | 67.9% | $156.8M | $19.70B |
| FY 2024 | $1.04B | $88.82B | 34.7% | 69.1% | $35.8M | $19.84B |
| FY 2023 | $1.05B | $85.16B | — | — | -$206.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
JNJ // BETA 1.08